IL-17A Increases Doxorubicin Efficacy in Triple Negative Breast Cancer

被引:4
作者
Hum, Nicholas R. [1 ,2 ]
Sebastian, Aimy [1 ]
Martin, Kelly A. [1 ]
Rios-Arce, Naiomy D. [1 ]
Gilmore, Sean F. [1 ]
Gravano, David M. [2 ]
Wheeler, Elizabeth K. [3 ]
Coleman, Matthew A. [1 ,4 ]
Loots, Gabriela G. [1 ,2 ]
机构
[1] Lawrence Livermore Natl Lab, Phys & Life Sci Directorate, Livermore, CA 94550 USA
[2] Univ Calif Merced, Stem Cell Instrumentat Foundry, Merced, CA 95343 USA
[3] Lawrence Livermore Natl Lab, Engn Directorate, Livermore, CA USA
[4] Univ Calif Davis, Dept Radiat Oncol, Sacramento, CA USA
关键词
triple negative breast cancer; doxorubicin; IL-17A; gamma delta T cells; chemoresistance; single cell RNA seq; LONG-TERM OUTCOMES; ADJUVANT CHEMOTHERAPY; CELLS; ACTIVATION; PATHWAY; CYTOTOXICITY; CONTRIBUTES; INFECTION; GROWTH; BLOOD;
D O I
10.3389/fonc.2022.928474
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Due to lack of targetable receptors and intertumoral heterogeneity, triple negative breast cancer (TNBC) remains particularly difficult to treat. Doxorubicin (DOX) is typically used as nonselective neoadjuvant chemotherapy, but the diversity of treatment efficacy remains unclear. Comparable to variability in clinical response, an experimental model of TNBC using a 4T1 syngeneic mouse model was found to elicit a differential response to a seven-day treatment regimen of DOX. Single-cell RNA sequencing identified an increase in T cells in tumors that responded to DOX treatment compared to tumors that continued to grow uninhibited. Additionally, compared to resistant tumors, DOX sensitive tumors contained significantly more CD4 T helper cells (339%), gamma delta T cells (727%), Naive T cells (278%), and activated CD8 T cells (130%). Furthermore, transcriptional profiles of tumor infiltrated T cells in DOX responsive tumors revealed decreased exhaustion, increased chemokine/cytokine expression, and increased activation and cytotoxic activity. gamma delta T cell derived IL-17A was identified to be highly abundant in the sensitive tumor microenvironment. IL-17A was also found to directly increase sensitivity of TNBC cells in combination with DOX treatment. In TNBC tumors sensitive to DOX, increased IL-17A levels lead to a direct effect on cancer cell responsiveness and chronic stimulation of tumor infiltrated T cells leading to improved chemotherapeutic efficacy. IL-17A's role as a chemosensitive cytokine in TNBC may offer new opportunities for treating chemoresistant breast tumors and other cancer types.
引用
收藏
页数:15
相关论文
共 74 条
[1]   IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients [J].
Ahmad, Narmeen ;
Ammar, Aula ;
Storr, Sarah J. ;
Green, Andrew R. ;
Rakha, Emad ;
Ellis, Ian O. ;
Martin, Stewart G. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (04) :537-549
[2]   Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials [J].
Alberro, J. A. ;
Ballester, B. ;
Deulofeu, P. ;
Fabregas, R. ;
Fraile, M. ;
Gubern, J. M. ;
Janer, J. ;
Moral, A. ;
de Pablo, J. L. ;
Penalva, G. ;
Puig, P. ;
Ramos, M. ;
Rojo, R. ;
Santesteban, P. ;
Serra, C. ;
Sola, M. ;
Solarnau, L. ;
Solsona, J. ;
Veloso, E. ;
Vidal, S. ;
Abe, O. ;
Abe, R. ;
Enomoto, K. ;
Kikuchi, K. ;
Koyama, H. ;
Masuda, H. ;
Nomura, Y. ;
Ohashi, Y. ;
Sakai, K. ;
Sugimachi, K. ;
Toi, M. ;
Tominaga, T. ;
Uchino, J. ;
Yoshida, M. ;
Coles, C. E. ;
Haybittle, J. L. ;
Moebus, V. ;
Leonard, C. F. ;
Calais, G. ;
Garaud, P. ;
Collett, V. ;
Davies, C. ;
Delmestri, A. ;
Sayer, J. ;
Harvey, V. J. ;
Holdaway, I. M. ;
Kay, R. G. ;
Mason, B. H. ;
Forbe, J. F. ;
Franci, P. A. .
LANCET ONCOLOGY, 2018, 19 (01) :27-39
[3]   Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast Cancer [J].
Alizadeh, Darya ;
Trad, Malika ;
Hanke, Neale T. ;
Larmonier, Claire B. ;
Janikashvili, Nona ;
Bonnotte, Bernard ;
Katsanis, Emmanuel ;
Larmonier, Nicolas .
CANCER RESEARCH, 2014, 74 (01) :104-118
[4]   AP-1 Transcription Factors as Regulators of Immune Responses in Cancer [J].
Atsaves, Vasileios ;
Leventaki, Vasiliki ;
Rassidakis, George Z. ;
Claret, Francois X. .
CANCERS, 2019, 11 (07)
[5]   Transcriptional insights into the CD8+ T cell response to infection and memory T cell formation [J].
Best, J. Adam ;
Blair, David A. ;
Knell, Jamie ;
Yang, Edward ;
Mayya, Viveka ;
Doedens, Andrew ;
Dustin, Michael L. ;
Goldrath, Ananda W. .
NATURE IMMUNOLOGY, 2013, 14 (04) :404-412
[6]   Th17 Cells and IL-17 As Novel Immune Targets in Ovarian Cancer Therapy [J].
Bilska, Monika ;
Pawlowska, Anna ;
Zakrzewska, Ewelina ;
Chudzik, Agata ;
Suszczyk, Dorota ;
Gogacz, Marek ;
Wertel, Iwona .
JOURNAL OF ONCOLOGY, 2020, 2020
[7]   EIF2A promotes cell survival during paclitaxel treatment in vitro and in vivo [J].
Chen, Lin ;
He, Jiang ;
Zhou, Jianhua ;
Xiao, Zhi ;
Ding, Nianhua ;
Duan, Yumei ;
Li, Wenzheng ;
Sun, Lun-Quan .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2019, 23 (09) :6060-6071
[8]   Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients [J].
Chen, Xi ;
Wan, Jin ;
Liu, Jiankun ;
Xie, Wei ;
Diao, Xinwei ;
Xu, Jianping ;
Zhu, Bo ;
Chen, Zhengtang .
LUNG CANCER, 2010, 69 (03) :348-354
[9]   Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model [J].
Christowitz, Claudia ;
Davis, Tanja ;
Isaacs, Ashwin ;
van Niekerk, Gustav ;
Hattingh, Suzel ;
Engelbrecht, Anna-Mart .
BMC CANCER, 2019, 19 (01)
[10]   IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2 [J].
Cochaud, Stephanie ;
Giustiniani, Jerome ;
Thomas, Clemence ;
Laprevotte, Emilie ;
Garbar, Christian ;
Savoye, Aude-Marie ;
Cure, Herve ;
Mascaux, Corinne ;
Alberici, Gilles ;
Bonnefoy, Nathalie ;
Eliaou, Jean-Francois ;
Bensussan, Armand ;
Bastid, Jeremy .
SCIENTIFIC REPORTS, 2013, 3